Corporate Strategy & Due Diligence
We partner with pharmaceutical companies and private equity investors to conduct commercial diligence for investments in products, portfolios and healthcare services.
200+ Commercial assessments conducted
75+ M&A transactions supported
30+ Search and evaluation projects completed
Project Types
Informed Decision-Making Through Corporate Strategy and Due Diligence
Corporate Strategy
- Portfolio strategy
- R&D Prioritization
- Opportunity Identification
- Growth Strategy
- Investor Material Development
Due Diligence
- Commercial Assessment
- Buy-Side Due Diligence (Licensing and M&A)
- Sell-Side Diligence
- Transaction Support
- Royalty Monetization
Our Corporate Strategy & Diligence Approach
Buy-Side Diligence
Objective
Evaluate licensing opportunity for late-stage novel therapeutic
Approach
Develop understanding of commercial landscape for multiple indications of interest
Conduct market research with key stakeholders to understand anticipated evolution of each market, future unmet needs, and potential positioning of therapeutic
Conduct market research and analog analysis to understand likely pricing and access for therapeutic within each relevant market
Provide strategic insights on optimal development pathway for therapeutic, opportunities, and risks
Provide recommendations for investment in the context of the commercial opportunity, commercial investment requirements, and commercial synergies
Opportunity Identification
Objective
Identify potential licensing/acquisition targets which fit corporate strategy/goals
Approach
Align on corporate goals and ideal investment characteristics to guide evaluation
Develop initial database of opportunities representing the “universe” of potential opportunities
Collaboratively identify key filtering criteria to refine list of opportunities to those which may represent the most attractive near-term investments
Manually review and characterize opportunities of interest to allow for “tiering”
Provide support in BD outreach for top tier opportunities